56P Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Year: 2024
Type: article
Abstract: IL13Ra2 CAR + IL12 was able to eliminate tumour over multiple infusions demonstrating sustained efficacy and no toxicity with this approach.Conclusions: Our SENDER platform enables CAR T cell production whilst minimising cell exhaustion and improving function.This process eliminated the need to purify, activate, transduce and expand T cells that are typically required for CAR T cell manufacturing, thus increasing the simplicity whilst reducing costs and production time.Potent armoured components can be expressed transiently and at controlled concentrations to maximise efficacy without causing toxicity.
Source: Immuno-Oncology Technology
Institutions: Siriraj Hospital, Mahidol University, Chiang Mai University
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,170
Award: G980294486
OpenAlex ID: W4405374630